First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015).

about

Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.Respiratory syncytial virus hospitalization and incurred morbidities the season after prophylaxis

P2860

Q38671952-1442BC40-1367-444B-8CE2-DB914CCBCCA2 Q58084597-3FA533C4-E0B1-4132-9AFA-30EECE706FF2

P2860

First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015).

Item

http://www.wikidata.org/entity/Q37660572

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 January 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

First versus second year respi ...... onic lung disease (2005-2015).

@en

First versus second year respiratory syncytial virus prophylaxis in chronic lung disease

@nl

type

Item

label

First versus second year respi ...... onic lung disease (2005-2015).

@en

First versus second year respiratory syncytial virus prophylaxis in chronic lung disease

@nl

prefLabel

First versus second year respi ...... onic lung disease (2005-2015).

@en

First versus second year respiratory syncytial virus prophylaxis in chronic lung disease

@nl

P1476

First versus second year respi ...... onic lung disease (2005-2015).

@en

P2093

Abby Li

http://www.w3.org/2001/XMLSchema#string

Bosco Paes

http://www.w3.org/2001/XMLSchema#string

CARESS Investigators

http://www.w3.org/2001/XMLSchema#string

Daniel Y Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective

Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection

A cost-benefit analysis of the immunisation of children against respiratory syncytial virus (RSV) using the English Hospital Episode Statistics (HES) data set.

High burden of RSV hospitalization in very young children: a data linkage study.

Outcomes of palivizumab prophylaxis for respiratory syncytial virus infection in preterm children with bronchopulmonary dysplasia at a single hospital in Korea from 2005 to 2009.

Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.

Respiratory syncytial virus prophylaxis--the story so far.

Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review.

Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention

P2888

s00431-017-2849-4

P304

413-422

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00431-017-2849-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

176

http://www.w3.org/2001/XMLSchema#string

P50

Krista L Lanctôt

Ian Mitchell

P577

2017-01-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28105526

http://www.w3.org/2001/XMLSchema#string

P932

5321716

http://www.w3.org/2001/XMLSchema#string

First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015).

about

P2860

P2860

First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015).

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932